PURPOSE: Since the 1970s, the use of metamizole is controversial due to the risk of agranulocytosis. The aim of this study was to analyze individual case safety reports (ICSRs) of metamizole-associated hematological adverse drug reactions (ADRs). METHODS: International and Swiss metamizole-associated ICSR concerning selected hematological ADR were retrieved from VigiBase™, the World Health Organization Global Database of ICSR, and the Swiss Pharmacovigilance Database. We evaluated demographic data, co-medication, drug administration information, dose and duration of metamizole treatment, as well as the latency time of ADR, their course, and severity. The subgroup analysis of Swiss reports allowed us to analyze cases with fatal outcome more in depth and to estimate a rough minimal incidence rate. RESULTS: A total of 1417 international and 77 Swiss reports were analyzed. Around 52 % of the international and 33 % of the Swiss metamizole-associated hematological ADR occurred within a latency time of ≤7 days. More women were affected. The annual number of hematological reports and those with fatal outcome increased over the last years parallel to metamizole sales figures. In Switzerland, the minimal incidence rate of agranulocytosis was 0.46-1.63 cases per million person-days of use (2006-2012). Female sex, old age, pancytopenia, and co-medication with methotrexate were striking characteristics of the seven Swiss fatal cases. CONCLUSIONS: Metamizole-associated hematological ADR remain frequently reported. This is underscored by increasing annual reporting rates, which mainly reflect growing metamizole use. Early detection of myelotoxicity and avoidance of other myelotoxic substances such as methotrexate are important measures for preventing fatalities.
PURPOSE: Since the 1970s, the use of metamizole is controversial due to the risk of agranulocytosis. The aim of this study was to analyze individual case safety reports (ICSRs) of metamizole-associated hematological adverse drug reactions (ADRs). METHODS: International and Swiss metamizole-associated ICSR concerning selected hematological ADR were retrieved from VigiBase™, the World Health Organization Global Database of ICSR, and the Swiss Pharmacovigilance Database. We evaluated demographic data, co-medication, drug administration information, dose and duration of metamizole treatment, as well as the latency time of ADR, their course, and severity. The subgroup analysis of Swiss reports allowed us to analyze cases with fatal outcome more in depth and to estimate a rough minimal incidence rate. RESULTS: A total of 1417 international and 77 Swiss reports were analyzed. Around 52 % of the international and 33 % of the Swiss metamizole-associated hematological ADR occurred within a latency time of ≤7 days. More women were affected. The annual number of hematological reports and those with fatal outcome increased over the last years parallel to metamizole sales figures. In Switzerland, the minimal incidence rate of agranulocytosis was 0.46-1.63 cases per million person-days of use (2006-2012). Female sex, old age, pancytopenia, and co-medication with methotrexate were striking characteristics of the seven Swiss fatal cases. CONCLUSIONS:Metamizole-associated hematological ADR remain frequently reported. This is underscored by increasing annual reporting rates, which mainly reflect growing metamizole use. Early detection of myelotoxicity and avoidance of other myelotoxic substances such as methotrexate are important measures for preventing fatalities.
Authors: Burkhard Hinz; Olga Cheremina; Jouri Bachmakov; Bertold Renner; Oliver Zolk; Martin F Fromm; Kay Brune Journal: FASEB J Date: 2007-04-13 Impact factor: 5.191
Authors: Tobias Rogosch; Christian Sinning; Agnes Podlewski; Bernhard Watzer; Joel Schlosburg; Aron H Lichtman; Maria G Cascio; Tiziana Bisogno; Vincenzo Di Marzo; Rolf Nüsing; Peter Imming Journal: Bioorg Med Chem Date: 2011-11-25 Impact factor: 3.641
Authors: Sebastian Klose; René Pflock; Inke R König; Roland Linder; Markus Schwaninger Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-12-07 Impact factor: 3.000
Authors: Ernane Souza; Ryan L Crass; Jeremy Felton; Kengo Hanaya; Manjunath P Pai Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Victoria C Ziesenitz; Frédérique Rodieux; Andrew Atkinson; Carole Borter; Julia A Bielicki; Manuel Haschke; Urs Duthaler; Fabio Bachmann; Thomas O Erb; Nicolas Gürtler; Stefan Holland-Cunz; Johannes N van den Anker; Verena Gotta; Marc Pfister Journal: Eur J Clin Pharmacol Date: 2019-08-07 Impact factor: 2.953
Authors: Rafael Barbosa de Araújo; Leandro Cabral Zacharias; Breno Marques de Azevedo; Beatrice Schmidt Giusti; Rony Carlos Pretti; Walter Y Takahashi; Mário Luiz Ribeiro Monteiro Journal: Int J Retina Vitreous Date: 2015-11-12
Authors: Björn Stessel; Michiel Boon; Elbert A Joosten; Jean-Paul Ory; Stefan Evers; Sander M J van Kuijk; Jasperina Dubois; Daisy Hoofwijk; Luc Jamaer; Wolfgang F F A Buhre Journal: Trials Date: 2016-09-26 Impact factor: 2.279